PIP‐CpG converts an immunosuppressive TME dominated by MDSCs into a lymphocyte‐rich TME that infiltrates activated CD8+ T cells, CD4+ T cells, and B cells and leads to a T‐cell‐mediated tumor‐specific immune response.305. Here, CD8A is linked to neoplasm.